Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
Open Access
- 28 May 2014
- journal article
- review article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-13
Abstract
Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visualize and characterize tumor lesions. Additionally, it can be used to identify patients who may benefit from a particular therapy and monitor the therapy outcome. In recent years the field is focused on89Zr, a radiometal with near ideal physical and chemical properties for immuno-PET. In this review we will discuss the production of 89Zr, the bioconjugation strategies, and applications in (pre-)clinical studies of 89Zr-based immuno-PET in oncology. To date,89Zr-based PET imaging has been investigated in a wide variety of cancer-related targets. Moreover, clinical studies have shown the feasibility for89Zr-based immuno-PET to predict and monitor treatment, which could be used to tailor treatment for the individual patient. Further research should be directed towards the development of standardized and robust conjugation methods and improved chelators to minimize the amount of released Zr4+from the antibodies. Additionally, further validation of the imaging method is required. The ongoing development of new89Zr-labeled antibodies directed against novel tumor targets is expected to expand applications of 89Zr-labeled immuno-PET to a valuable method in the medical imaging.Keywords
This publication has 101 references indexed in Scilit:
- Routine Production of 89Zr Using an Automated ModuleApplied Sciences, 2013
- 89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining ChallengesMolecules, 2013
- Evaluation of 89Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic CancerPLOS ONE, 2013
- Cetuximab: its unique place in head and neck cancer treatmentBiologics: Targets and Therapy, 2013
- Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click ChemistryBioconjugate Chemistry, 2011
- Quantitative imaging of 124I and 86Y with PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of DiseaseChemical Reviews, 2010
- Standardized methods for the production of high specific-activity zirconium-89Nuclear Medicine and Biology, 2009
- p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009